Shots:
From AI-powered discovery to next-generation biologics and gene editing, 2025 was a blockbuster year for life sciences dealmaking. Pharma and biotech companies signed multibillion-dollar partnerships and acquisitions to accelerate innovation across oncology, cardiometabolic diseases, neurology, and rare disorders.
Platform technologies dominated the deal landscape, with big pharma securing access to cutting-edge modalities from bispecific…
Shots:
The P-II trial assessed 5 doses of petrelintide (SC, QW) vs PBO for 42wks. in 493 overweight or obese pts (mean BMI of 37 kg/m²) with weight-related comorbidities
Trial met its 1EP, with Q4W dose-escalated injections delivering significant weight loss across 5 arms after 28wks. & sustaining ~10.7% vs 1.7% mean reduction through Wk.…
Shots:
Zealand Pharma has entered into a multi-program strategic collaboration & license agreement with OTR to discover & develop oral small molecules for metabolic diseases
OTR & Zealand will jointly discover & develop multiple metabolic disease therapies, with OTR using its discovery platform to lead discovery & preclinical work while Zealand will handle global clinical…
Shots:
Zealand Pharma & Roche will develop & market petrelintide & its products incl. petrelintide + CT-388 (Roche’s asset) in the US & EU for weight loss, with Roche obtaining exclusive marketing rights in the rest of the world
Zealand will handle ~50% marketing in the US & EU with opt-in/out rights under specific…
In an interview with PharmaShots, Dr. David Kendall, Senior Global Medical Advisor at Zealand Pharma shared his views on the availability of Zegalogue in the US for severe hypoglycemia in pediatric and adult patients with diabetes & its availability in both an auto-injector and a prefilled syringe
Shots:
The company reported the availability of Zegalogue (0.6mg/0.6mL) in the US…
In an interview with PharmaShots, Emmanuel Dulac, Pharm.D., Ph.D., President and CEO of Zealand Pharma shares insight on the US FDA's approval of Zegalogue and its availability in both an auto-injector and a prefilled syringe in June 2021. He also highlighted the importance of approval for the company and patients with hypoglycemia.
Shots:
The approval is based…

